The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.
As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route.
Browse the Report Summary at: www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis
Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016.
The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.
The research finds that different companies collaborated for the development of BACE inhibitors. Novartis entered in a global collaboration with Amgen to commercialize and develop BACE inhibitor program in September 2015 for Alzheimer's disease.
Explore Report Sample at: www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample
Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information:Make an Inquiry about this report HERE!